Amgen Launches First Humira (adalimumab) Biosimilar Amjevita in the US

Shots:

The company has launched Amjevita (adalimumab), the first biosimilar referencing blockbuster drug Humira on the US market for certain serious inflammatory diseases. Amjevita will be available in a prefilled syringe & auto-injector pen
Amjevita (40mg) is available with 2 pricing options. One pricing will be a 5% discount below the current list price of Humira while the other pricing will be a 55% discount. Multiple other adalimumab biosimilars are set to launch in the US in July 2023
In Sept 2016, Amjevita was the first adalimumab biosimilar to be approved in the US & is also available in the EU & Canada. The company provides a patient support program i.e., AMJEVITA SupportPlus incl. financial support information & educational resources

Ref: Amgen | Image: Amgen

Related News:- Prime Therapeutics will Include Biosimilars to the NetResults Formulary in Addition to Humira